A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants with Relapsed or Refractory Multiple Myeloma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503441-55-00

Acronym

64007957MMY3001

Enrollment

310

Registered

2024-07-16

Start date

2021-10-14

Completion date

Unknown

Last updated

2025-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/Refractory Multiple Myeloma

Brief summary

PFS

Interventions

DRUGteclistamab

DRUGPomalidomide

DRUGDexamethasone Tablets BP 2.0mg

DRUGImnovid 3 mg hard capsules

DRUGPrivigen 100 mg/ml solution for infusion

DRUGImnovid 1 mg hard capsules

DRUGDexamethason 8 mg GALEN® Tabletten

DRUGFortecortin® 2 mg Tabletten

DRUGImnovid 4 mg hard capsules

DRUGImnovid 2 mg hard capsules

DRUGVELCADE 3.5 mg powder for solution for injection

DRUGDARZALEX 1800 mg solution for injection

DRUGDexamethason 4 mg JENAPHARM®

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
PFS	—

Countries

Belgium, Denmark, France, Germany, Greece, Italy, Netherlands, Poland, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026